Atara Biotherapeutics (NASDAQ:ATRA) Rating Reiterated by HC Wainwright

Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports.

Other research analysts have also issued reports about the stock. StockNews.com assumed coverage on shares of Atara Biotherapeutics in a research note on Wednesday, June 26th. They issued a “hold” rating on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $13.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, August 13th. The Goldman Sachs Group decreased their price objective on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a report on Wednesday, July 17th. Finally, Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and dropped their target price for the stock from $25.00 to $18.00 in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $185.50.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $7.18 on Wednesday. Atara Biotherapeutics has a fifty-two week low of $4.96 and a fifty-two week high of $49.00. The firm has a market capitalization of $34.59 million, a PE ratio of -0.13 and a beta of 0.52. The stock’s 50-day simple moving average is $9.20 and its 200-day simple moving average is $14.52.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The business had revenue of $28.64 million during the quarter, compared to the consensus estimate of $48.30 million. Sell-side analysts forecast that Atara Biotherapeutics will post -15.75 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. Vontobel Holding Ltd. purchased a new position in Atara Biotherapeutics in the fourth quarter worth approximately $41,000. BNP Paribas Financial Markets grew its holdings in shares of Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 86,842 shares during the period. Acadian Asset Management LLC increased its position in shares of Atara Biotherapeutics by 49.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after purchasing an additional 873,133 shares during the last quarter. Delap Wealth Advisory LLC purchased a new stake in Atara Biotherapeutics in the 1st quarter valued at about $29,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Atara Biotherapeutics by 8,916.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after buying an additional 4,903,159 shares during the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.